06/01/2026
Join Joel Brierre, Founder & CEO of KVI, for a frank and wide-ranging conversation on one of the most fascinating — and complex — frontiers in modern medicine and entrepreneurship: 5-MeO-DMT.
Joel has been a pioneer in the modern psychedelic movement, specifically in the realm of 5-MeO-DMT, applying classical non-dual yogic philosophy as geography for both preparation and integration from the entheogenic experience. With KVI, he has built an ecosystem that sits at the intersection of retreat operations, academic research, and emerging biotech — collaborating with top universities including University College London to study the effects of 5-MeO-DMT in naturalistic ceremonial settings.
In this episode, we go deep on what it actually takes to build, fund, and scale a company in a grey-area market — and why the science behind this molecule may reshape psychiatry, neuroscience, and drug development for decades to come.
ďż˝ Insights You'll Learn:
What Makes 5-MeO-DMT Different: Why this compound occupies a category of its own among psychedelics — and what the emerging neuroscience is revealing about consciousness, the self, and the brain.
The World's First EEG Study of the 5-MeO Peak: What happened when researchers measured brain electrical activity in participants who inhaled 5-MeO-DMT — and what the dramatic surge in slow brain waves, fragmenting into chaotic patterns across the cortex, tells us about this state of consciousness.
Building in the Grey Area: The legal, regulatory, and reputational challenges of scaling a psychedelic company — and how Joel has navigated them without compromising the integrity of the work.
The Retreat Business Model: What it takes to build safe, effective, and scalable retreat operations, and how KVI has professionalized a space that was once entirely underground.
From Retreats to Biotech: How non-hallucinogenic analogs of 5-MeO-DMT are being developed to treat neurodegenerative diseases — and why the neuroplastogen space is just getting started.
Raising Capital in Psychedelics: The unique challenges of investor education, deal structure, and fundraising in a market where the regulatory landscape is still forming.
The UCL Collaboration: How KVI's partnership with UCL is gathering quantitative and qualitative data from retreat participants to assess changes in wellbeing, beliefs, and personality — and what individualized approaches to 5-MeO-DMT therapy could look like.
ďż˝ Why This Matters:
Mental health, treatment-resistant depression, PTSD, and neurodegeneration represent some of the largest unmet needs in global healthcare. 5-MeO-DMT is used in synthetic form at Tandava Retreats due to concerns over species conservation and the sustainability of sourcing the substance at scale — a detail that underscores the serious, methodical thinking Joel brings to this work. The molecule's therapeutic potential is extraordinary, but realizing it requires the kind of rigorous science, business discipline, and ethical leadership that KVI is quietly building.
ďż˝ Expert Background:
Founder & CEO of KVI — an ecosystem for discovering the unique potentials of 5-MeO-DMT through research, retreats, and biotech development.
Research Collaborator with leading universities including UCL, executing some of the world's first formal neurological studies of the 5-MeO-DMT peak experience.
Retreat Pioneer with over a decade of experience curating safe, evidence-informed 5-MeO-DMT experiences for participants worldwide.
Biotech Co-Founder developing non-hallucinogenic analogs of 5-MeO-DMT targeting neurodegenerative disease and brain injury.
Author and educator — contributing to the psychedelic industry's shift toward rigorous harm reduction, ethical sourcing, and scientific legitimacy.
� Hosted by Gary Fowler, CEO of GSD Venture Studios — global AI entrepreneur, investor, and innovation leader spotlighting founders navigating the realities of building in the AI era.
ďż˝ Perfect For:
Mental health investors and operators, biotech founders, psychedelic industry professionals, neuroscience researchers, wellness entrepreneurs, and anyone curious about the frontier of consciousness science and the business models emerging around it.
ďż˝ Timely Topic:
The psychedelic industry is at an inflection point — moving from cultural curiosity to clinical credibility. Joel Brierre is one of the few operators who has built simultaneously across retreats, research, and drug development, giving him a uniquely complete view of where this space is headed — and what it will take to get there responsibly.
Subscribe for more global founder conversations from GSD Venture Studios: https://gsdvs.com
